John G. Saia, Chief Legal Officer at Guardant Health, Inc. (NASDAQ:GH), completed a sale of company common stock totaling $1,250,835 on May 27, 2026. This transaction was documented in a recent filing with the Securities and Exchange Commission.
Mr. Saia's disposals involved 10,000 shares across two distinct transactions. The sale prices for these shares ranged from $125.083 to $126.08 per share. Specifically, the larger portion of the sale consisted of 9,994 shares, sold at a weighted average price of $125.083 per share. These shares were liquidated through multiple sales, with individual transaction prices observed between $125.00 and $125.44. Complementing this, an additional six shares were disposed of at a rate of $126.08 per share.
The timing of this insider sale is noteworthy given Guardant Health's recent market performance. The company's stock trades near its 52-week high of $133.71, reflecting a substantial 249% return over the past year. Despite these gains, an analysis from InvestingPro suggests that the stock may be currently valued highly.
From a corporate valuation standpoint, Guardant Health maintains a company value of $16.9 billion. The firm continues to demonstrate robust revenue growth, posting 40% increases in revenue, even while remaining unprofitable. Following these transactions, Mr. Saia's direct ownership stake in Guardant Health common stock stands at 35,950 shares.
Recent Financial and Regulatory Developments
In parallel to the insider trading activity, Guardant Health released its Q1 2026 earnings report, which presented a mixed picture of financial performance. The company reported total revenue of $302 million for the quarter. This figure surpassed market expectations, exceeding forecasts by 8.04%. However, the earnings per share (EPS) disappointed analysts, falling to -$0.85 against a forecast that projected -$0.81.
A major positive development highlighted during this period was the U.S. Food and Drug Administration's approval of Guardant Health’s Guardant360 Liquid CDx. This blood-based cancer testing product offers a more extensive genomic analysis capability compared to its previous iteration. The receipt of this FDA clearance was noted as being earlier than anticipated.
The positive regulatory news spurred immediate reactions from investment analysts. TD Cowen reiterated its Buy rating and maintained a price target of $127.00 for Guardant Health. Furthermore, BTIG increased its price target on Guardant Health shares to $155, up from $145, while keeping the Buy rating. Stifel also upheld a Buy rating, setting a price target at $130.00, and emphasized the positive feedback received from key opinion leaders within the colorectal cancer screening domain.
Collectively, these reports underscore Guardant Health’s continued progress in the field of cancer diagnostics and reflect sustained investor interest in the company's advancements.